Compare Stocks: LCTX, ALVO, JBIO, and LXRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVO Alvotech	$4.05 -1.0%	$3.67	$2.94 ▼ $9.25	$1.23B	0.18	869,565 shs	607,247 shs
JBIO Jade Biosciences	$24.71 +3.8%	$20.23	$6.67 ▼ $28.00	$1.51B	1.49	803,573 shs	1.48 million shs
LCTX Lineage Cell Therapeutics	$1.07 +0.9%	$1.19	$1.00 ▼ $2.09	$268.08M	1.53	966,960 shs	1.13 million shs
LXRX Lexicon Pharmaceuticals	$2.32 -0.9%	$2.25	$1.03 ▼ $2.68	$1.04B	1.08	2.89 million shs	1.76 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVO Alvotech	-0.98%	+6.30%	+19.82%	+22.36%	-54.80%
JBIO Jade Biosciences	+3.78%	+12.52%	+13.04%	+5.82%	+237.11%
LCTX Lineage Cell Therapeutics	+0.94%	-2.73%	-12.30%	-14.40%	+3.88%
LXRX Lexicon Pharmaceuticals	-0.85%	-6.07%	+5.45%	+4.04%	+109.01%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVO Alvotech	$4.05 -1.0%	$3.67	$2.94 ▼ $9.25	$1.23B	0.18	869,565 shs	607,247 shs
JBIO Jade Biosciences	$24.71 +3.8%	$20.23	$6.67 ▼ $28.00	$1.51B	1.49	803,573 shs	1.48 million shs
LCTX Lineage Cell Therapeutics	$1.07 +0.9%	$1.19	$1.00 ▼ $2.09	$268.08M	1.53	966,960 shs	1.13 million shs
LXRX Lexicon Pharmaceuticals	$2.32 -0.9%	$2.25	$1.03 ▼ $2.68	$1.04B	1.08	2.89 million shs	1.76 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVO Alvotech	-0.98%	+6.30%	+19.82%	+22.36%	-54.80%
JBIO Jade Biosciences	+3.78%	+12.52%	+13.04%	+5.82%	+237.11%
LCTX Lineage Cell Therapeutics	+0.94%	-2.73%	-12.30%	-14.40%	+3.88%
LXRX Lexicon Pharmaceuticals	-0.85%	-6.07%	+5.45%	+4.04%	+109.01%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALVO Alvotech	2.14	Hold	$7.60	87.65% Upside
JBIO Jade Biosciences	2.90	Moderate Buy	$51.75	109.43% Upside
LCTX Lineage Cell Therapeutics	3.00	Buy	$6.25	484.11% Upside
LXRX Lexicon Pharmaceuticals	2.25	Hold	$4.55	96.12% Upside

Current Analyst Ratings Breakdown

Latest LCTX, ALVO, JBIO, and LXRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	ALVO Alvotech	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
8/11/2026	JBIO Jade Biosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$48.00
8/10/2026	JBIO Jade Biosciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$45.00 ➝ $47.00
8/10/2026	JBIO Jade Biosciences	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$74.00 ➝ $77.00
8/3/2026	LXRX Lexicon Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/23/2026	LXRX Lexicon Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/14/2026	LCTX Lineage Cell Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/8/2026	LXRX Lexicon Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/3/2026	LXRX Lexicon Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
6/18/2026	LXRX Lexicon Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/16/2026	JBIO Jade Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)

(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALVO Alvotech	$588.90M	2.08	$0.22 per share	18.77	($0.94) per share	-4.31
JBIO Jade Biosciences	N/A	N/A	N/A	N/A	$6.92 per share	N/A
LCTX Lineage Cell Therapeutics	$14.56M	18.59	N/A	N/A	$0.24 per share	4.46
LXRX Lexicon Pharmaceuticals	$49.80M	20.73	N/A	N/A	$0.39 per share	5.95

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALVO Alvotech	$27.92M	-$0.25	N/A	12.66	N/A	-14.36%	-11.92%	-7.59%	8/19/2026 (Estimated)
JBIO Jade Biosciences	-$127.41M	-$1.92	N/A	N/A	N/A	N/A	-49.11%	-45.62%	N/A
LCTX Lineage Cell Therapeutics	-$63.53M	-$0.12	N/A	N/A	N/A	-246.58%	-73.06%	-30.87%	N/A
LXRX Lexicon Pharmaceuticals	-$50.34M	-$0.15	N/A	N/A	N/A	-147.38%	-37.53%	-24.96%	N/A

Latest LCTX, ALVO, JBIO, and LXRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/19/2026	Q2 2026	ALVO Alvotech	-$0.0526	N/A	N/A	N/A	$103.00 million	N/A
8/10/2026	Q2 2026	JBIO Jade Biosciences	-$0.66	-$0.76	-$0.10	-$0.76	N/A	N/A
8/6/2026	Q2 2026	LCTX Lineage Cell Therapeutics	-$0.0283	-$0.03	-$0.0017	-$0.03	$1.84 million	$1.07 million
8/6/2026	Q2 2026	LXRX Lexicon Pharmaceuticals	-$0.0502	-$0.06	-$0.0098	-$0.07	$3.99 million	$0.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALVO Alvotech	N/A	N/A	N/A	N/A	N/A
JBIO Jade Biosciences	N/A	N/A	N/A	N/A	N/A
LCTX Lineage Cell Therapeutics	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALVO Alvotech	N/A	1.76	0.88
JBIO Jade Biosciences	N/A	14.93	14.29
LCTX Lineage Cell Therapeutics	N/A	6.61	6.89
LXRX Lexicon Pharmaceuticals	0.29	13.37	13.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALVO Alvotech	N/A
JBIO Jade Biosciences	N/A
LCTX Lineage Cell Therapeutics	62.47%
LXRX Lexicon Pharmaceuticals	74.70%

Insider Ownership

Company	Insider Ownership
ALVO Alvotech	0.46%
JBIO Jade Biosciences	23.06%
LCTX Lineage Cell Therapeutics	24.70%
LXRX Lexicon Pharmaceuticals	14.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALVO Alvotech	1,460	301.81 million	300.42 million	Not Optionable
JBIO Jade Biosciences	20	63.60 million	48.93 million	N/A
LCTX Lineage Cell Therapeutics	60	252.91 million	190.44 million	Not Optionable
LXRX Lexicon Pharmaceuticals	140	444.96 million	382.66 million	Optionable

LCTX, ALVO, JBIO, and LXRX Headlines

Recent News About These Companies

Lexicon (LXRX) Q2 2026 Earnings Call Transcript

August 13 at 3:27 PM | finance.yahoo.com

Lexicon Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 10, 2026 | seekingalpha.com

Renaissance Technologies LLC Increases Holdings in Lexicon Pharmaceuticals, Inc. $LXRX

August 10, 2026 | marketbeat.com

HC Wainwright Issues Optimistic Outlook for LXRX Earnings

August 10, 2026 | americanbankingnews.com

HC Wainwright Issues Positive Forecast for LXRX Earnings

August 10, 2026 | marketbeat.com

Wall Street Zen Downgrades Lexicon Pharmaceuticals (NASDAQ:LXRX) to Sell

August 8, 2026 | americanbankingnews.com

Lexicon Pharmaceuticals (NASDAQ:LXRX) Rating Lowered to "Sell" at Wall Street Zen

August 8, 2026 | marketbeat.com

Lexicon Pharmaceuticals (NASDAQ:LXRX) Announces Earnings Results, Misses Estimates By $0.01 EPS

August 7, 2026 | marketbeat.com

Lexicon Pharmaceuticals Q2 Earnings Call Highlights

August 6, 2026 | marketbeat.com

Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates

August 6, 2026 | zacks.com

Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Gap Down on Disappointing Earnings

August 6, 2026 | marketbeat.com

Lexicon: Q2 Earnings Snapshot

August 6, 2026 | chron.com

Lexicon Pharmaceuticals Reports Q2 2026 Results; Completes Enrollment in Phase 3 SONATA-HCM Study and Advances ZYNQUISTA NDA Resubmission

August 6, 2026 | quiverquant.comQ

Lexicon Pharmaceuticals Q2 revenue falls to $0.7 million amid clinical updates

August 6, 2026 | quiverquant.comQ

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

August 6, 2026 | globenewswire.com

Lexicon Pharmaceuticals Q2 2026 earnings preview

August 5, 2026 | msn.com

Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Rating Lowered by Zacks Research

August 5, 2026 | marketbeat.com

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

July 30, 2026 | globenewswire.com

Lexicon Pharmaceuticals (LXRX) As Phase 3 Enrollment Beats Plan Faces An Undervalued View

July 30, 2026 | finance.yahoo.com

750,000 Shares in Lexicon Pharmaceuticals, Inc. $LXRX Purchased by ADAR1 Capital Management LLC

July 30, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LCTX, ALVO, JBIO, and LXRX Company Descriptions

Alvotech NASDAQ:ALVO

$4.05 -0.04 (-0.98%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$4.03 -0.02 (-0.62%)

As of 08/14/2026 07:50 PM Eastern

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Jade Biosciences NASDAQ:JBIO

$24.71 +0.90 (+3.78%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$24.72 +0.00 (+0.02%)

As of 08/14/2026 07:34 PM Eastern

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Lineage Cell Therapeutics NYSEAMERICAN:LCTX

$1.07 +0.01 (+0.94%)

Closing price 08/14/2026 04:10 PM Eastern

Extended Trading

$1.08 +0.01 (+0.56%)

As of 08/14/2026 08:00 PM Eastern

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Lexicon Pharmaceuticals NASDAQ:LXRX

$2.32 -0.02 (-0.85%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$2.34 +0.02 (+0.65%)

As of 08/14/2026 07:34 PM Eastern

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LCTX, ALVO, JBIO, and LXRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LCTX, ALVO, JBIO, and LXRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LCTX, ALVO, JBIO, and LXRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LCTX, ALVO, JBIO, and LXRX Company Descriptions

Alvotech NASDAQ:ALVO

Jade Biosciences NASDAQ:JBIO

Lineage Cell Therapeutics NYSEAMERICAN:LCTX

Lexicon Pharmaceuticals NASDAQ:LXRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LCTX, ALVO, JBIO, and LXRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LCTX, ALVO, JBIO, and LXRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LCTX, ALVO, JBIO, and LXRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LCTX, ALVO, JBIO, and LXRX Company Descriptions

Alvotech NASDAQ:ALVO

Jade Biosciences NASDAQ:JBIO

Lineage Cell Therapeutics NYSEAMERICAN:LCTX

Lexicon Pharmaceuticals NASDAQ:LXRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools